WallStreetZenWallStreetZen

NASDAQ: MNPR
Monopar Therapeutics Stock Ownership - Who owns Monopar Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Monopar Therapeutics insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Chandler RobinsonChief Executive Officer2025-07-1416,800$40.00
$672.02kSell
Chandler RobinsonChief Executive Officer2025-07-1416,800$0.01
$84.00Buy
Kim R. TsuchimotoDirector2025-07-148,904$40.00
$356.17kSell
Kim R. TsuchimotoDirector2025-07-148,904$0.01
$44.52Buy
Christopher M. StarrDirector2025-07-1416,800$40.00
$672.02kSell
Christopher M. StarrDirector2025-07-1416,800$0.01
$84.00Buy
Andrew CittadineChief Operating Officer2025-06-302,990$35.78
$106.98kSell
Chandler RobinsonChief Executive Officer2025-06-305,865$35.78
$209.85kSell
Tactic Pharma LLCChief Executive Officer2025-04-0233,334$35.00
$1.17MSell
Chandler RobinsonChief Executive Officer2025-03-311,204$36.41
$43.84kSell

1 of 2

MNPR insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when MNPR insiders and whales buy or sell their stock.

MNPR Shareholders

What type of owners hold Monopar Therapeutics stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Arthur J. Klausner149.06%9,197,045$452.68MInsider
Tactic Pharma LLC79.96%4,933,528$242.83MInsider
Michael J. 1. Brown77.88%4,805,470$236.53MInsider
Janus Henderson Group PLC19.00%1,172,368$57.70MInstitution
Chandler Robinson14.52%895,727$44.09MInsider
Adage Capital Partners GP LLC9.71%599,195$29.49MInstitution
Ra Capital Management LP8.29%511,207$25.16MInstitution
Blackrock Inc3.33%205,169$10.10MInstitution
Andrew Paul Mazar3.06%188,792$9.29MInsider
Christopher M. Starr1.85%113,853$5.60MInsider

1 of 3

MNPR vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
MNPR13.57%86.43%Net SellingNet Selling
LCTX39.04%60.96%Net Buying
IMRX10.54%38.57%Net BuyingNet Buying
SCPH63.32%36.68%Net Selling
GLUE34.03%65.97%Net Selling
View Top Biotech Stocks

Monopar Therapeutics Stock Ownership FAQ

Who owns Monopar Therapeutics?

Monopar Therapeutics (NASDAQ: MNPR) is owned by 51.48% institutional shareholders, 327.95% Monopar Therapeutics insiders, and 0.00% retail investors. Arthur J. Klausner is the largest individual Monopar Therapeutics shareholder, owning 9.20M shares representing 149.06% of the company. Arthur J. Klausner's Monopar Therapeutics shares are currently valued at $452.68M.

If you're new to stock investing, here's how to buy Monopar Therapeutics stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.